|
Market Closed -
Nasdaq
04:00:00 07/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 502.31 USD | -0.24% |
|
-4.64% | +10.80% |
| 09-28 | UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating | MT |
| 09-23 | TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating | MT |
| Market Cap | 127B 113B 106B 95.86B 181B 12,273B 182B 1,270B 494B 6,261B 478B 468B 20,128B | P/E 2026 * |
51.6x | P/E 2027 * | 27.2x |
|---|---|---|---|---|---|
| Enterprise Value | 122B 108B 101B 91.69B 173B 11,739B 174B 1,215B 473B 5,988B 457B 447B 19,251B | EV / Sales 2026 * |
9.19x | EV / Sales 2027 * | 8.09x |
| Free-Float |
99.79% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VRTX | Delayed | |
CBOE
| VRTX | Real-time | |
|
Tradegate
| VX1 | Real-time | |
|
London S.E.
| 0QZU | Delayed | |
|
Mexican S.E.
| VRTX * | End-of-day quote | |
|
Borsa Italiana
| 1VRTX | End-of-day quote | |
|
Xetra
| VX1 | Delayed | |
|
Deutsche Boerse AG
| VX1 | Delayed | |
|
Wiener Boerse
| VRTX | End-of-day quote | |
|
Börse Stuttgart
| VX1 | Delayed | |
|
Boerse Muenchen
| VX1 | Real-time | |
|
CBOE
| 0QZU | Real-time | |
|
CBOE
| Real-time |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | -0.24% | ||
| 1 week | -4.64% | ||
| Current month | -3.92% | ||
| 1 month | -8.02% | ||
| 3 months | -5.15% | ||
| 6 months | +15.66% | ||
| Current year | +10.80% |
| 1 week | 496.15 |  | 523.52 |
| 1 month | 496.15 | | 535 |
| Current year | 412.27 | | 560.25 |
| 1 year | 402.58 | | 560.25 |
| 3 years | 341.9 | | 560.25 |
| 5 years | 177.71 | | 560.25 |
| 10 years | 71.46 | | 560.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 01/04/2020 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 10/04/2019 |
Sean Daughtry
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 66 | 01/01/1998 |
Jeffrey Leiden
CHM | Chairman | 70 | 01/05/2012 |
Sangeeta Bhatia
BRD | Director/Board Member | 57 | 18/06/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 28/8/26 | Free | Controller/Auditor | 5,000 | 0.0020% | ||
| 27/8/26 | Don | Director | -6,000 | 0.0024% | ||
| 21/7/26 | Free | General Counsel | 8,251 | 0.0033% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.24% | -4.64% | +24.67% | +39.29% | 127B | |
| +1.26% | -2.29% | +36.97% | +104.79% | 1,032B | |
| +0.73% | -4.78% | +35.41% | +61.62% | 614B | |
| +0.35% | +1.29% | +15.86% | +79.90% | 471B | |
| +1.72% | -4.92% | +59.84% | +36.64% | 350B | |
| +0.99% | +1.69% | +23.05% | +41.52% | 337B | |
| +0.90% | -1.13% | +12.78% | +34.57% | 268B | |
| -0.16% | -2.41% | -6.23% | +10.39% | 246B | |
| -0.09% | -4.97% | +36.88% | +50.52% | 218B | |
| -0.28% | -4.66% | +26.99% | +92.98% | 179B | |
| Average | +0.15% | -3.51% | +26.62% | +55.22% | 384.22B | |
| Weighted average by Cap. | +0.27% | -3.23% | +29.66% | +66.33% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.25B 11.76B 11.01B 9.98B 18.84B 1,277B 18.98B 132B 51.41B 651B 49.73B 48.66B 2,094B | 14.55B 12.92B 12.09B 10.96B 20.69B 1,403B 20.84B 145B 56.47B 716B 54.62B 53.45B 2,300B |
| Net income | 2.54B 2.25B 2.11B 1.91B 3.61B 244B 3.63B 25.3B 9.84B 125B 9.52B 9.31B 401B | 4.84B 4.29B 4.02B 3.64B 6.88B 466B 6.93B 48.25B 18.77B 238B 18.15B 17.76B 765B |
| Net Debt | -5.54B -4.92B -4.6B -4.17B -7.88B -534B -7.94B -55.3B -21.51B -273B -20.8B -20.36B -876B | -9.58B -8.5B -7.96B -7.21B -13.62B -923B -13.72B -95.57B -37.17B -471B -35.96B -35.19B -1,514B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/10/26 | US$502.31 | -0.24% | 775,071 |
| 05/10/26 | US$503.50 | -0.24% | 915,135 |
| 02/10/26 | US$504.73 | -0.40% | 939,658 |
| 01/10/26 | US$506.74 | -3.07% | 1,194,639 |
| 30/09/26 | US$522.81 | -0.74% | 1,146,002 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VRTX Stock
Select your edition
All financial news and data tailored to specific country editions
